Article citationsMore >>

Nishimoto, N., Miyasaka, N., Yamamoto, K., Kawai, S., Takeuchi, T., Azuma, J., “Long-term safety and efficacy of tocilizumab, an anti-IL-6 receptor monoclonal antibody, in monotherapy, in patients with rheumatoid arthritis (the STREAM study): evidence of safety and efficacy in a 5-year extension study”, Ann Rheum Dis, 68 (10). 1580-4. 2009.

has been cited by the following article:

Article

Clinical Outcomes in Rheumatoid Arthritis due to Tocilizumab Stock-out during COVID-19 Epidemics: A Short Case Series Report

1Faculty of Medicine and Biomedical Sciences, University of Algarve, Faro, Portugal

2University of Algarve, School of Health, Faro, Portugal

3Algarve Biomedical Center Research Institute - ABCRI, Faro, Portugal

4Centro Hospitalar Universitário do Algarve, Faro, Portugal

5Algarve Biomedical Center Research Institute - ABCRI, Faro, Portugal;Comprehensive Health Research Centre - CHRC, Lisboa, Portugal


American Journal of Medical Case Reports. 2022, Vol. 10 No. 10, 271-273
DOI: 10.12691/ajmcr-10-10-5
Copyright © 2022 Science and Education Publishing

Cite this paper:
Inês Barbosa, Ezequiel Pinto, Maria Graça Sequeira Munoz, Tânia Nascimento, Sandra Pais. Clinical Outcomes in Rheumatoid Arthritis due to Tocilizumab Stock-out during COVID-19 Epidemics: A Short Case Series Report. American Journal of Medical Case Reports. 2022; 10(10):271-273. doi: 10.12691/ajmcr-10-10-5.

Correspondence to: Ezequiel  Pinto, University of Algarve, School of Health, Faro, Portugal. Email: epinto@ualg.pt

Abstract

This short case-series reports a 6-month follow up of 5 rheumatoid arthritis patients (2 males, 3 females) 60 years-old or above, with Tocilizumab treatment which was discontinued due to stock off in July 2021. Patients switched treatment to other DMARD (Upadacitinib, Baricitinib, or Certolizumab pegol). We report clinical data and the Disease Activity Score for Rheumatoid Arthritis. Upadacitinib, Baricitinib, and Certolizumab appear therapeutically equivalent to Tocilizumab in a 6-month follow-up.

Keywords